You can buy or sell EBS and other stocks, options, ETFs, and crypto commission-free!
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. Read More Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.
52 Week High
52 Week Low
Health And Wellness
Yahoo FinanceMar 23
Emergent Biosolutions (EBS) Down 24.2% Since Last Earnings Report: Can It Rebound?
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. It has been about a month since the last earnings report for Emergent Biosolutions (EBS). Shares have lost about 24.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Emergent Biosolutions due for a breakout? Before we dive into how investors and analysts have reacted as of late, le...
Present Movement: Emergent Biosolutions (NYSE: EBS)
Emergent Biosolutions trades as part of the biotechnology industry and is part of the healthcare sector. The company CEO is Daniel J. Abdun-Nabi. Emergent BioSolutions Inc is a biotechnology company operating in two divisions: biodefense and biosciences. The company focuses on countermeasures that address public health threats around hematology and oncology therapeutics. Previous Intraday Trading Performance: The EBS stock showed a previous change of -1.81% with an open at 48.86 and a close of 48.23. It r...
Yahoo FinanceMar 20
Emergent Begins Phase III Study on Anthrax Vaccine AV7909
Emergent BioSolutions Inc. EBS announced that it has initiated a phase III study to evaluate AV7909 for the post-exposure prophylaxis of anthrax disease. The phase III program will evaluate the lot consistency, immunogenicity and safety of AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) following a two-dose schedule, administered intramuscularly in healthy adult patients. AV7909 is currently being developed for post-exposure prophylaxis of anthrax disease, resulting from a suspected Bacillus anthr...
Expected May 2, After Hours